期刊
INTERNATIONAL JOURNAL OF GENERAL MEDICINE
卷 14, 期 -, 页码 3833-3848出版社
DOVE MEDICAL PRESS LTD
DOI: 10.2147/IJGM.S295459
关键词
type 2 diabetes; monotherapy; combination therapies; efficacy; safety outcomes
The study analyzed the advantages of metformin-based combination therapy over diabetes monotherapy, finding that combination therapy is more likely to achieve durable glycemic control with better tolerability.
Step-wise addition of antihyperglycemic agents (AHA) after the initiation of metformin monotherapy has been the traditional approach for the treatment of type 2 diabetes mellitus (T2DM) world-wide. Emerging evidence increasingly suggests that metformin-based combination therapy, especially with the newer AHA that lowers HbA1c glucose-dependently and do not potentiate hypoglycemia, could be a potentially better option for durable glycemic control with good tolerability compared to diabetes monotherapy. In this review, we descriptively analyzed the evidence available from the systematic reviews and meta-analyses of randomized head-to-head trials that reported the efficacy and safety outcomes of diabetes monotherapy, metformin-based combination therapies, and monotherapy versus metformin-based combination therapies.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据